Imipenem heteroresistance induced by imipenem in multidrug-resistant Acinetobacter baumannii

Mechanism and clinical implications

Hao Yuan Lee, Chyi Liang Chen, Shi Bo Wang, Lin Hui Su, Shu Hung Chen, Shu Ying Liu, Tsu Lan Wu, Tzou Yien Lin, Cheng Hsun Chiu

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Acinetobacter baumannii has emerged as a major pathogen causing nosocomial infections, particularly in critical patients admitted to the Intensive Care Unit. Increasing resistance to carbapenems in A. baumannii has been observed worldwide. Here we report the clinical impact and mechanism of imipenem heteroresistance (imipenem minimum inhibitory concentration of 6-32 μg/mL with the presence of resistant cells inside the inhibition zone of Etest strips or disks) in multidrug-resistant A. baumannii (MDR-AB). To identify risk factors associated with the emergence of imipenem heteroresistance, a retrospective case-control study was undertaken involving cases with subsequent clinical isolates of the same genotype showing loss of imipenem susceptibility and matched controls with isolates belonging to imipenem-susceptible MDR-AB. The molecular mechanism of heteroresistance was examined. From April 2006 to March 2007, 126 consecutive isolates of MDR-AB were identified from 29 patients. Switch from imipenem susceptibility to heteroresistance was more likely to occur in successive MDR-AB derived from patients who had been exposed to imipenem (length of use 10.9 ± 6.5 days for cases vs. 5.3 ± 4.8 days for controls; P = 0.02). An insertion sequence (ISAba1) was found in the promoter region of a class C β-lactamase gene (blaADC-29) in most imipenem-heteroresistant MDR-AB isolates. In vitro experiments indicated that imipenem heteroresistance, which was associated with overexpression of bla ADC-29, could be induced by imipenem. Carbapenem use was the only risk factor identified for the emergence of carbapenem-heteroresistant MDR-AB. Physicians should weigh the benefits and risks of each carbapenem-based treatment in managing carbapenem-susceptible MDR-AB infection.

Original languageEnglish
Pages (from-to)302-308
Number of pages7
JournalInternational Journal of Antimicrobial Agents
Volume37
Issue number4
DOIs
Publication statusPublished - Apr 2011
Externally publishedYes

Fingerprint

Acinetobacter baumannii
Imipenem
Carbapenems
Disk Diffusion Antimicrobial Tests
Acinetobacter Infections
Insertional Mutagenesis
Microbial Sensitivity Tests
Cross Infection
Genetic Promoter Regions
Intensive Care Units
Case-Control Studies
Genotype
Physicians

Keywords

  • Acinetobacter baumannii
  • Carbapenem
  • Heteroresistance
  • Imipenem
  • Multidrug resistance

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Imipenem heteroresistance induced by imipenem in multidrug-resistant Acinetobacter baumannii : Mechanism and clinical implications. / Lee, Hao Yuan; Chen, Chyi Liang; Wang, Shi Bo; Su, Lin Hui; Chen, Shu Hung; Liu, Shu Ying; Wu, Tsu Lan; Lin, Tzou Yien; Chiu, Cheng Hsun.

In: International Journal of Antimicrobial Agents, Vol. 37, No. 4, 04.2011, p. 302-308.

Research output: Contribution to journalArticle

Lee, Hao Yuan ; Chen, Chyi Liang ; Wang, Shi Bo ; Su, Lin Hui ; Chen, Shu Hung ; Liu, Shu Ying ; Wu, Tsu Lan ; Lin, Tzou Yien ; Chiu, Cheng Hsun. / Imipenem heteroresistance induced by imipenem in multidrug-resistant Acinetobacter baumannii : Mechanism and clinical implications. In: International Journal of Antimicrobial Agents. 2011 ; Vol. 37, No. 4. pp. 302-308.
@article{24062d6cd0c04a31942b7781f80323f2,
title = "Imipenem heteroresistance induced by imipenem in multidrug-resistant Acinetobacter baumannii: Mechanism and clinical implications",
abstract = "Acinetobacter baumannii has emerged as a major pathogen causing nosocomial infections, particularly in critical patients admitted to the Intensive Care Unit. Increasing resistance to carbapenems in A. baumannii has been observed worldwide. Here we report the clinical impact and mechanism of imipenem heteroresistance (imipenem minimum inhibitory concentration of 6-32 μg/mL with the presence of resistant cells inside the inhibition zone of Etest strips or disks) in multidrug-resistant A. baumannii (MDR-AB). To identify risk factors associated with the emergence of imipenem heteroresistance, a retrospective case-control study was undertaken involving cases with subsequent clinical isolates of the same genotype showing loss of imipenem susceptibility and matched controls with isolates belonging to imipenem-susceptible MDR-AB. The molecular mechanism of heteroresistance was examined. From April 2006 to March 2007, 126 consecutive isolates of MDR-AB were identified from 29 patients. Switch from imipenem susceptibility to heteroresistance was more likely to occur in successive MDR-AB derived from patients who had been exposed to imipenem (length of use 10.9 ± 6.5 days for cases vs. 5.3 ± 4.8 days for controls; P = 0.02). An insertion sequence (ISAba1) was found in the promoter region of a class C β-lactamase gene (blaADC-29) in most imipenem-heteroresistant MDR-AB isolates. In vitro experiments indicated that imipenem heteroresistance, which was associated with overexpression of bla ADC-29, could be induced by imipenem. Carbapenem use was the only risk factor identified for the emergence of carbapenem-heteroresistant MDR-AB. Physicians should weigh the benefits and risks of each carbapenem-based treatment in managing carbapenem-susceptible MDR-AB infection.",
keywords = "Acinetobacter baumannii, Carbapenem, Heteroresistance, Imipenem, Multidrug resistance",
author = "Lee, {Hao Yuan} and Chen, {Chyi Liang} and Wang, {Shi Bo} and Su, {Lin Hui} and Chen, {Shu Hung} and Liu, {Shu Ying} and Wu, {Tsu Lan} and Lin, {Tzou Yien} and Chiu, {Cheng Hsun}",
year = "2011",
month = "4",
doi = "10.1016/j.ijantimicag.2010.12.015",
language = "English",
volume = "37",
pages = "302--308",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Imipenem heteroresistance induced by imipenem in multidrug-resistant Acinetobacter baumannii

T2 - Mechanism and clinical implications

AU - Lee, Hao Yuan

AU - Chen, Chyi Liang

AU - Wang, Shi Bo

AU - Su, Lin Hui

AU - Chen, Shu Hung

AU - Liu, Shu Ying

AU - Wu, Tsu Lan

AU - Lin, Tzou Yien

AU - Chiu, Cheng Hsun

PY - 2011/4

Y1 - 2011/4

N2 - Acinetobacter baumannii has emerged as a major pathogen causing nosocomial infections, particularly in critical patients admitted to the Intensive Care Unit. Increasing resistance to carbapenems in A. baumannii has been observed worldwide. Here we report the clinical impact and mechanism of imipenem heteroresistance (imipenem minimum inhibitory concentration of 6-32 μg/mL with the presence of resistant cells inside the inhibition zone of Etest strips or disks) in multidrug-resistant A. baumannii (MDR-AB). To identify risk factors associated with the emergence of imipenem heteroresistance, a retrospective case-control study was undertaken involving cases with subsequent clinical isolates of the same genotype showing loss of imipenem susceptibility and matched controls with isolates belonging to imipenem-susceptible MDR-AB. The molecular mechanism of heteroresistance was examined. From April 2006 to March 2007, 126 consecutive isolates of MDR-AB were identified from 29 patients. Switch from imipenem susceptibility to heteroresistance was more likely to occur in successive MDR-AB derived from patients who had been exposed to imipenem (length of use 10.9 ± 6.5 days for cases vs. 5.3 ± 4.8 days for controls; P = 0.02). An insertion sequence (ISAba1) was found in the promoter region of a class C β-lactamase gene (blaADC-29) in most imipenem-heteroresistant MDR-AB isolates. In vitro experiments indicated that imipenem heteroresistance, which was associated with overexpression of bla ADC-29, could be induced by imipenem. Carbapenem use was the only risk factor identified for the emergence of carbapenem-heteroresistant MDR-AB. Physicians should weigh the benefits and risks of each carbapenem-based treatment in managing carbapenem-susceptible MDR-AB infection.

AB - Acinetobacter baumannii has emerged as a major pathogen causing nosocomial infections, particularly in critical patients admitted to the Intensive Care Unit. Increasing resistance to carbapenems in A. baumannii has been observed worldwide. Here we report the clinical impact and mechanism of imipenem heteroresistance (imipenem minimum inhibitory concentration of 6-32 μg/mL with the presence of resistant cells inside the inhibition zone of Etest strips or disks) in multidrug-resistant A. baumannii (MDR-AB). To identify risk factors associated with the emergence of imipenem heteroresistance, a retrospective case-control study was undertaken involving cases with subsequent clinical isolates of the same genotype showing loss of imipenem susceptibility and matched controls with isolates belonging to imipenem-susceptible MDR-AB. The molecular mechanism of heteroresistance was examined. From April 2006 to March 2007, 126 consecutive isolates of MDR-AB were identified from 29 patients. Switch from imipenem susceptibility to heteroresistance was more likely to occur in successive MDR-AB derived from patients who had been exposed to imipenem (length of use 10.9 ± 6.5 days for cases vs. 5.3 ± 4.8 days for controls; P = 0.02). An insertion sequence (ISAba1) was found in the promoter region of a class C β-lactamase gene (blaADC-29) in most imipenem-heteroresistant MDR-AB isolates. In vitro experiments indicated that imipenem heteroresistance, which was associated with overexpression of bla ADC-29, could be induced by imipenem. Carbapenem use was the only risk factor identified for the emergence of carbapenem-heteroresistant MDR-AB. Physicians should weigh the benefits and risks of each carbapenem-based treatment in managing carbapenem-susceptible MDR-AB infection.

KW - Acinetobacter baumannii

KW - Carbapenem

KW - Heteroresistance

KW - Imipenem

KW - Multidrug resistance

UR - http://www.scopus.com/inward/record.url?scp=79952817869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952817869&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2010.12.015

DO - 10.1016/j.ijantimicag.2010.12.015

M3 - Article

VL - 37

SP - 302

EP - 308

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

IS - 4

ER -